USA flag logo/image

An Official Website of the United States Government

Medications for Alcohol Withdrawal/Brain Damage

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
29075
Program Year/Program:
1997 / SBIR
Agency Tracking Number:
29075
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
LOHOCLA RESEARCH CORPORATION
12635 E. Montview Blvd. AURORA, CO 80045-7337
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1997
Title: Medications for Alcohol Withdrawal/Brain Damage
Agency: HHS
Contract: 1 R43 AA09930-01A1,
Award Amount: $748,637.00
 

Abstract:

Chronic ethanol ingestion results in neurodegeneration with loss of neurons, glial proliferation anventricular and subarachnoid space. Work from our laboratories has demonstrated that chronic ethanolanimals produces an up-regulation of the excitatory N-methyl-D-aspartate (NMDA) subtype of glutamateWe have recently implicated the NMDA receptor system in induction of excitotoxic damage to various nduring ethanol withdrawal. We will test a series of compounds for their effectiveness in protectingcerebellum and cerebral cortex, grown in culture, against ethanol withdrawal induced excitotoxic damthe effectiveness of a novel NMDA receptor channel blocker, (+)-5- aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine(ADCI), which we have previously shown to be an excellent agent fobehavioral hyperexcitability (tremor, convulsions) during ethanol withdrawal in animals. We will alscycloleucine, and low efficacy partial agonists i.e.,; 1-neuroprotective actions in our cell culturewithdrawal excitotoxicity. Finally, we will test a series of gangliosides, including GM1 and GT1b, shave been touted to protect against glutamate-induced excitotoxicity without compromising the initiarelated events accompanying NMDA receptor stimulation. Our studies will generate an understanding ofcompounds are most effective for preventing ethanol withdrawal excitotoxicity and provide a basis foanimals in Phase II of the SBIR program.

Principal Investigator:

Lawrence Snell
31286

Business Contact:

Small Business Information at Submission:

Lohocla Research Corp.
505 Chicago Avenue Evanston, IL 60202

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No